ALSO READGlenmark Pharma draws up capex of USD 300 mn over next 3 yrs Glenmark Pharma gets USFDA nod for hypertension drug Glenmark Pharma's Ankleshwar plant gets 4 FDA observations Glenmark Pharma gains after USFDA approval for Tretinoin capsules Glenmark Pharma gets healthier after getting USFDA nod for generic drug
From USFDAGlenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca AB.
According to IMS Health sales data for the 12 month period ending April 2017, the Onglyza Tablets, 2.5 mg and 5 mg market1 achieved annual sales of approximately $518.5 million.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)